开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 11-14 16:08:09

2.100

+0.060

+2.94%

最高2.190	最低1.970	成交量449.30万
今开2.000	昨收2.040	日振幅10.78%
总市值9.83亿	流通市值9.83亿	总股本4.68亿
成交额946.90万	换手率0.96%	流通股本4.68亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.1,"timestamp":1763107689894,"preClose":2.04,"halted":0,"volume":4493000,"delay":0,"floatShares":468000000,"shares":468000000,"eps":-0.3945092018876433,"marketStatus":"休市中","change":0.06,"latestTime":"11-14 16:08:09","open":2,"high":2.19,"low":1.97,"amount":9469035,"amplitude":0.107843,"askPrice":2.1,"askSize":69000,"bidPrice":2.09,"bidSize":12000,"shortable":0,"etf":0,"ttmEps":-0.4226341100555099,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763343000000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.04,"openAndCloseTimeList":[[1763083800000,1763092800000],[1763096400000,1763107200000]],"volumeRatio":1.8862300588216514,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2583651829","title":"每周股票复盘：海正药业（600267）挂牌转让医药子公司股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651829","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651829?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:14","pubTimestamp":1763234053,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，海正药业报收于11.26元，较上周的10.93元上涨3.02%。公司公告汇总浙江海正药业股份有限公司于2025年8月22日召开第十届董事会第六次会议，审议通过转让全资子公司浙江省医药工业有限公司100%股权的议案。浙江海正药业股份有限公司于2025年11月12日召开2025年第二次临时股东会，审议通过了关于参与浙江圣兆药物科技股份有限公司股票定向发行及与其共同投资设立复杂注射剂合资公司的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK1161","BK0239","09939","BK0060","BK1574","BK0028","600267","BK0188"],"gpt_icon":0},{"id":"2583651393","title":"三季报总结 | 天风医药：医疗设备行业及个股2025三季度回顾与展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651393","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651393?lang=zh_cn&edition=full","pubTime":"2025-11-15 17:00","pubTimestamp":1763197200,"startTime":"0","endTime":"0","summary":"2025Q3板块业绩曙光初现，费用率同比持平2025Q3营收同比增长，前三季度整体业绩承压。毛利率同比下降，费用率同比持平。毛利率下降主要因为国内医疗器械集采和地方设备更新相关的招采对于国内市场的产品价格压力较大。预计2025Q4营业收入同比增速相较Q3将有望提升。其中CT整体和磁共振整体的同比增速分别高达86%和72%。公司预计海外业务2025全年仍将保持高速增长态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649147845&idx=5&sn=9b7a46d4ac8832fa872f61ff4cdf5041&chksm=82ef67c98004889b8df0416b13a6ad2d769d7b15189bbf470096cb88525795f892b36dcf0e62&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1515","BK1161","09939","BK1574"],"gpt_icon":0},{"id":"2583022115","title":"人福医药：公司始终专注于医药主业的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2583022115","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583022115?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:10","pubTimestamp":1763129400,"startTime":"0","endTime":"0","summary":"证券日报网讯人福医药（维权）11月14日在互动平台回答投资者提问时表示，公司始终专注于医药主业的发展，持续推进“归核聚焦”工作，优化资产结构，强化细分领域竞争优势。2025年前三季度，公司实现归母净利润16.89亿元，同比增长6.22%，2025年三季度末公司资产负债率降至40.53%，资产结构持续改善。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxktkn8977482.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxktkn8977482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","600079","09939","BK1574","BK0070","BK1161","BK0012","BK0185","159938","BK0096","BK0188","BK1515","BK0239"],"gpt_icon":0},{"id":"2583542501","title":"国药控股主业遇冷，医药流通龙头的增长神话还能延续吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583542501","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583542501?lang=zh_cn&edition=full","pubTime":"2025-11-14 21:23","pubTimestamp":1763126625,"startTime":"0","endTime":"0","summary":"作为国内医药流通行业的龙头企业，国药控股（股票代码：1099.HK）近期的业绩表现引发了市场的广泛关注。尽管其营收规模在行业内持续保持领先地位，但陷入净利润增长显著放缓的困境。业绩承压的背后，是公司三大核心业务板块集体面临增长挑战。作为营收“压舱石”的医药分销业务增长乏力，医疗器械板块同样未能摆脱增长瓶颈，就连曾被寄予厚望的医药零售业务，其增长也伴随着战略调整的阵痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511143565047652.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511143565047652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1197","LU0640798160.USD","LU1115378108.SGD","BK1500","01099","BK1574","BK1515","BK1161","09939"],"gpt_icon":0},{"id":"2583503742","title":"科兴制药(688136.SH)：科益医药拟询价转让5%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2583503742","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583503742?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:15","pubTimestamp":1763122501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科兴制药(688136.SH)披露股东询价转让计划书，本次拟参与本次询价转让的股东为科益医药，拟转让股份的总数为1006.28万股，占公司总股本的比例为5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369553.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688136","BK1574","09939","BK1515","159938","BK0239","BK1161"],"gpt_icon":0},{"id":"2583505330","title":"富祥药业：他唑巴坦、舒巴坦是公司主要医药产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2583505330","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583505330?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:09","pubTimestamp":1763122140,"startTime":"0","endTime":"0","summary":"证券日报网讯富祥药业11月14日发布公告，在公司回答调研者提问时表示，他唑巴坦、舒巴坦是公司主要医药产品，2024年销售收入占公司营业收入40%左右。而6-apa是他唑巴坦、舒巴坦的主要原材料，根据万得数据显示，截至2025年11月3日，6-apa价格较2024年底下降38%。随着其价格下降，将有效提升公司医药制造业务毛利率。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxkpau4340288.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-14/doc-infxkpau4340288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","300497","09939","BK1515","BK0201","BK0239","BK1161","159938"],"gpt_icon":0},{"id":"2583508925","title":"新股消息 | 融泰药业拟港股上市 中国证监会要求补充说明近一年内新增股东入股价格的合理性等","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508925","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583508925?lang=zh_cn&edition=full","pubTime":"2025-11-14 19:32","pubTimestamp":1763119944,"startTime":"0","endTime":"0","summary":"中国证监会国际司公示10家企业补充材料要求，其中，公示提到要求融泰药业补充说明最近12个月内新增股东入股价格的合理性等事项。中国证监会请融泰药业补充说明以下事项，请律师核查并出具明确的法律意见：一、请说明最近12个月内新增股东入股价格的合理性，该等入股价格之间存在差异的原因，是否存在利益输送。据招股书，融泰药业是中国领先的院外医药服务商，专注于数字化营销和供应链解决方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369520.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2583686606","title":"劲方医药-B11月14日获主力加仓80.3万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583686606","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583686606?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:15","pubTimestamp":1763108141,"startTime":"0","endTime":"0","summary":"11月14日, 劲方医药-B股价涨2.37%，报收32.00元，成交金额5231.2万元，换手率0.48%，振幅13.69%，量比1.68。劲方医药-B今日主力资金净流入80.3万元，上一交易日主力净流入140.3万元。该股近5个交易日上涨18.52%，主力资金累计净流入1208.4万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入1212.5万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111416194295041427&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111416194295041427&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","02595","BK1161","09939"],"gpt_icon":0},{"id":"2583454527","title":"11月14日开开实业（600272）涨停分析：SPD业务增长、医药数智化驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2583454527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583454527?lang=zh_cn&edition=full","pubTime":"2025-11-14 15:16","pubTimestamp":1763104579,"startTime":"0","endTime":"0","summary":"证券之星消息，开开实业11月14日涨停收盘，收盘价15.47元。该股于9点35分涨停，2次打开涨停，截止收盘封单资金为2160.98万元，占其流通市值0.87%。近5日资金流向一览见下表：该股为医药商业，医疗耗材供应链SPD，民营医院概念热股，当日医药商业概念上涨1.98%，医疗耗材供应链SPD概念上涨1.65%，民营医院概念上涨1.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400019077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0099","600272","BK1515","BK1161","09939","BK0184","BK0209","BK1574"],"gpt_icon":0},{"id":"2583852564","title":"午评：沪指半日跌0.16% 医药商业板块涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2583852564","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583852564?lang=zh_cn&edition=full","pubTime":"2025-11-14 12:43","pubTimestamp":1763095382,"startTime":"0","endTime":"0","summary":"中国经济网北京11月14日讯 A股三大指数今日震荡调整，截至午间收盘，上证指数报4022.89点，跌幅0.16%；深证成指报13327.91点，跌幅1.10%；创业板指报3146.01点，跌幅1.74%。\r\n\r\n　　板块方面，医药商业、燃气、厨卫电器、港口航运等涨幅居前，非金属材料、半导体、电子化学品、元件等跌幅居前。\r\n\r\n　　A股市场板块涨跌幅排行","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202511/14/20251114344866.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202511/14/20251114344866.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251114/31795889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["399006","159938","399001","000905.SH","159982","BK1161","000688.SH","515890","000300.SH","BK1574","510880","512880","510300","BK1515","512510","159967","000001.SH","09939"],"gpt_icon":0},{"id":"2583528672","title":"华特达因：医药业务净利润7.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583528672","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583528672?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:37","pubTimestamp":1763091437,"startTime":"0","endTime":"0","summary":"证券之星消息，华特达因(000915)11月14日在投资者关系平台上答复投资者关心的问题。投资者提问：您好贵公司三季度报告中，表述医药业务净利润7.57亿，但是实际是4.08亿，请问其中少去的2.5亿是哪个行业亏损造成的？谢谢华特达因回复：您好！公司医药业务主要由控股子公司达因药业及达因康健、达因高科运营。2025年前三季度，该板块实现净利润7.57亿元。按照持股比例计算，归属于上市公司股东的净利润为4.08亿元。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400014953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","000915","159938"],"gpt_icon":0},{"id":"2583852856","title":"开拓药业涨超5%拟折让15.03%发行认购股份筹资用于KX-826 III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2583852856","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583852856?lang=zh_cn&edition=full","pubTime":"2025-11-14 11:24","pubTimestamp":1763090640,"startTime":"0","endTime":"0","summary":"港股开拓药业-B(09939)涨超5%，截至发稿涨幅达5.39%，报2.15港元，成交额554.45万港元。消息面上，开拓药业-B发布公告，2025年11月12日，公司拟向华圆管理咨询(香港)有限公司（中新苏州工业园区创业投资有限公司全资拥有）发行3048.75万股认购股份，每股认购价1.64港元，较最后交易日收市价每股1.93港元折让约15.03%，此次认购事项净筹约4978万港元，资金拟用于集团日常业务的一般营运及KX-826的III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141135309503a123&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511141135309503a123&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1161","BK1574","BK1515"],"gpt_icon":0},{"id":"2583506980","title":"大型药商最新业绩比拼！上药、九州通、重药控股...","url":"https://stock-news.laohu8.com/highlight/detail?id=2583506980","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583506980?lang=zh_cn&edition=full","pubTime":"2025-11-14 10:25","pubTimestamp":1763087137,"startTime":"0","endTime":"0","summary":"两家大型药商前三季度营收突破千亿归母净利润有三家前三季度超十亿A股医药流通企业营收排名前十包括：上海医药、九州通、重药控股、国药一致、南京医药、国药股份、中国医药、英特集团、海王生物、鹭燕医药。2025年前三季度营收为622.11亿，同比增长4.22%；归母净利润为3.84亿元，同比增长31.41%。全国龙头药商如上海医药、九州通的业务均覆盖了全国31省/市/自治区。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114102634a4a05a47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114102634a4a05a47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02607","BK1574","09939","BK1161","BK1197"],"gpt_icon":0},{"id":"2583754346","title":"时迈药业拟赴香港上市；映恩生物治疗恶性实体瘤创新药获批临床丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2583754346","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583754346?lang=zh_cn&edition=full","pubTime":"2025-11-14 07:14","pubTimestamp":1763075693,"startTime":"0","endTime":"0","summary":"丨2025年11月14日星期五丨NO.1时迈药业拟赴香港上市港交所官网显示，浙江时迈药业递交上市申请，华泰国际为独家保荐人。据悉，时迈药业成立于2017年，作为下一代T细胞衔接器(TCE)疗法的先驱企业，旨在利用并引导人体免疫系统对抗癌症的下一代免疫疗法，公司已开发下一代先锋疗法遮蔽型TCE，可在肿瘤中被选择性激活，用于治疗实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511143563982352.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511143563982352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1161","BK1515","BK1574","09939"],"gpt_icon":0},{"id":"2583596636","title":"森萱医药（920946）披露投资者关系活动记录表，11月13日股价上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583596636","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583596636?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:17","pubTimestamp":1763043445,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，森萱医药报收于12.5元，较前一交易日上涨5.22%，最新总市值为53.36亿元。该股当日开盘11.91元，最高13.03元，最低11.87元，成交额达2.09亿元，换手率为3.86%。公司近日发布公告，披露了投资者关系活动记录表内容。公告显示，江苏森萱医药股份有限公司于2025年11月12日通过网络远程方式召开2025年第三季度报告业绩说明会，公司董事长吴玉祥、副董事长兼总经理袁拥军、董秘兼财务负责人朱狮章出席。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1161","BK1574","159938","BK1515"],"gpt_icon":0},{"id":"2583656495","title":"大兴机场临空经济区全球招商伙伴大会释放重磅合作机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2583656495","media":"中国金融信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583656495?lang=zh_cn&edition=full","pubTime":"2025-11-13 19:38","pubTimestamp":1763033880,"startTime":"0","endTime":"0","summary":"11月12日，以“聚全球资源 筑临空生态”为主题的2025第五届大兴机场临空经济区全球招商伙伴大会成功举办，三大临空特色产业服务平台集中亮相，超百万平方米高品质产业空间夯实发展基础，吸引近百家全球知名企业家、投资机构代表齐聚新国门，共赴合作机遇盛宴。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-11-13/doc-infxhkcq9956309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","BK1574","09939"],"gpt_icon":0},{"id":"2583554140","title":"新股前瞻|港股再迎CXO新势力，海纳医药“含金量”几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583554140","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583554140?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:21","pubTimestamp":1763022073,"startTime":"0","endTime":"0","summary":"近日，据港交所披露，南京海纳医药科技股份有限公司向港交所主板提交上市申请书，中金公司为其独家保荐人。截至2025年上半年末，海纳医药仍有398个正在进行的CXO项目。除CXO服务外，海纳医药还拥有自主立项的专有管线。于往绩记录期间，海纳医药签订了67份药物技术转让协议。尽管具有一定的成长性，但与国内聚焦创新药的CXO龙头企业相比，海纳医药主要布局仿制药领域，技术门槛相对较低。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","159938","09939","BK1161","CXO"],"gpt_icon":0},{"id":"2583655101","title":"劲方医药-B(02595.HK)尾盘涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583655101","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583655101?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:04","pubTimestamp":1763021075,"startTime":"0","endTime":"0","summary":"每经AI快讯，劲方医药-B(02595.HK)尾盘涨超8%，截至发稿，涨7.46%，报31.1港元，成交额2808.49万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511133563551168.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511133563551168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","BK1515","BK1574","BK1161","02595"],"gpt_icon":0},{"id":"2583551384","title":"港股异动 | 劲方医药-B(02595)尾盘涨超8% GFH375片启动III期临床 适应症为转移性胰腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2583551384","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583551384?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:53","pubTimestamp":1763020410,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，劲方医药-B尾盘涨超8%，截至发稿，涨7.46%，报31.1港元，成交额2808.49万港元。消息面上，11月11日，药物临床试验登记与信息公示平台显示，劲方医药开启了一项比较GFH375单药与研究者选择化疗治疗KRAS G12D突变型经治转移性胰腺癌患者的有效性及安全性/耐受性的多中心、开放标签、随机对照的III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","BK1574","09939","III","BK4134","BK1161","02595"],"gpt_icon":0},{"id":"2583553195","title":"新股前瞻|维健医药：趁着2025年上半年收入翻倍赶考","url":"https://stock-news.laohu8.com/highlight/detail?id=2583553195","media":"智通财经","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583553195?lang=zh_cn&edition=full","pubTime":"2025-11-13 14:37","pubTimestamp":1763015841,"startTime":"0","endTime":"0","summary":"2025年上半年，上述三大疾病产品收入份额分别为37.6%、25.1%及19.9%，另外其他产品收入份额17.4%。前五大客户收入贡献稳定，2022年至2025年上半年分别为60.2%、54.8%、59.8%及61.1%，不过最大客户收入贡献持续提升，上半年提升至25.7%。目前提供罗普司亭药物的主要有两家药企，分别是维健医药及齐鲁制药，其中维健医药的Romiplate惠尔凝于2022年1月首次获批上市，且已纳入国家医保目录，具备较大的竞争优势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1574","BK1515","BK1161","09939"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.2281},{"period":"1month","weight":-0.0233},{"period":"3month","weight":-0.1102},{"period":"6month","weight":0.7213},{"period":"1year","weight":0.8261},{"period":"ytd","weight":1.1649}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0255},{"period":"3month","weight":0.0515},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.3672},{"period":"ytd","weight":0.3247}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是临床阶段新药开发商。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.063412},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.078845},{"month":12,"riseRate":0.2,"avgChangeRate":-0.215118}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}